Izumi M, Larsen P R
J Clin Invest. 1977 Jun;59(6):1105-12. doi: 10.1172/JCI108734.
Previous studies have suggested that there is an overproduction of triiodothyronine (T(3)) relative to thyroxine (T(4)) in patients with thyrotoxicosis associated with Graves' disease. To evaluate whether or not an increased ratio of T(3) to T(4) in thyroidal secretion could be contributing to this relative T(3) hyperproduction, T(3), T(4), and iodine were measured in thyroglobulin (Tg) from controls and patients with Graves' disease who had been treated either with propranolol only or with antithyroid drugs plus iodide before surgery. To avoid possible artifacts associated with pulse labeling and chromatography, T(3) and T(4) were determined by radioimmunoassay of Pronase hydrolysates of purified Tg. Results of analyses of Tg from six control patients and seven with Graves' disease, not receiving thiourea drugs or iodide, showed that the iodine content of Graves' disease Tg was not different from normal. Both contained 3.4 residues of T(4)/molecule Tg, but there was 0.39+/-0.08 (mean+/-SD) residue of T(3)/molecule Tg in Graves' Tg as opposed to 0.23+/-0.07 residue T(3) molecule Tg in controls matched for iodine content (P < 0.01). This difference resulted in a significantly lower T(4)/T(3) molar ratio (9+/-2) in Graves' Tg as opposed to control (15+/-2, P < 0.001). In Tg from patients with treated Graves' disease, iodine, T(3), and T(4) were reduced, but the reduction in the latter was more substantial, resulting in a T(4)/T(3) molar ratio of 3.4+/-1. Fractionation of Tg from all groups by RbCl density gradient ultracentrifugation indicated that at physiological levels of Tg iodination, the molar ratio of T(3)/Tg was consistently higher in Graves' disease. The specific mechanism for this difference is not known, but it is not due to iodine deficiency. If T(3) and T(4) are secreted in this altered ratio in patients with Graves' disease, the magnitude of the difference could explain the relative T(3) hyperproduction which is characteristic of this state.
以往研究表明,患有格雷夫斯病相关甲状腺毒症的患者相对于甲状腺素(T4)而言,三碘甲状腺原氨酸(T3)产生过多。为评估甲状腺分泌物中T3与T4比值增加是否可能导致这种相对的T3产生过多,对对照组以及术前仅接受普萘洛尔治疗或接受抗甲状腺药物加碘治疗的格雷夫斯病患者的甲状腺球蛋白(Tg)中的T3、T4和碘进行了测量。为避免与脉冲标记和色谱法相关的可能假象,通过对纯化Tg的链霉蛋白酶水解产物进行放射免疫测定来确定T3和T4。对6名未接受硫脲类药物或碘的对照患者和7名格雷夫斯病患者的Tg分析结果表明,格雷夫斯病Tg的碘含量与正常无异。两者均含有3.4个T4残基/分子Tg,但格雷夫斯病Tg中含有0.39±0.08(均值±标准差)个T3残基/分子Tg,而碘含量匹配的对照组中为0.23±0.07个T3残基/分子Tg(P<0.01)。这种差异导致格雷夫斯病Tg中的T4/T3摩尔比(9±2)显著低于对照组(15±2,P<0.001)。在接受治疗的格雷夫斯病患者的Tg中,碘、T3和T4均减少,但后者减少更为显著,导致T4/T3摩尔比为3.4±1。通过RbCl密度梯度超速离心对所有组的Tg进行分级分离表明,在生理水平的Tg碘化时,格雷夫斯病中T3/Tg的摩尔比始终较高。这种差异的具体机制尚不清楚,但并非由于碘缺乏。如果格雷夫斯病患者以这种改变的比例分泌T3和T4,这种差异的程度可以解释这种状态所特有的相对T3产生过多现象。